Information Use and Disclosure Sample Clauses

The Information Use and Disclosure clause defines how parties may collect, use, and share information obtained during their relationship. Typically, it outlines the types of information covered, such as confidential business data or personal information, and sets boundaries on how this information can be disclosed to third parties or used for purposes beyond the agreement. This clause is essential for protecting sensitive data, ensuring compliance with privacy laws, and clarifying each party’s responsibilities regarding information handling.
Information Use and Disclosure. Bunge collects Personal Information from the Deliverer and Warehouser for the purpose of providing the services set out in the Bunge Warehouse Agreement. The Warehouser and Deliverer agree that its delivery details may be provided by Bunge at its discretion to: (a) marketers /traders for the purpose of promoting their services to the Warehouser and Deliverer; (b) the NGR or its agents for the purposes of the NGR or for promoting goods or services of other companies of relevance to the Warehouser; and (c) any organisation to which the Warehouser has donated Grain for the purpose of allowing the organization to identify the donor, (d) any adviser, auditor or member of the Bunge Group, including companies which may be located in other countries and otherwise may only be provided to other parties with the consent of the Warehouser. Bunge’s privacy policy is set out on the Website. All notices, requests to access or change information or privacy complaints should be made in writing to “The Privacy Officer”, Bunge Grain <<Address>>
View SourceView Similar (5)
Information Use and Disclosure. A. Neither Party (or its contractors) assumes any liability with respect to the accuracy and use of products developed by ARAC and WSPEEDI and exchanged by way of the prototype communications link. B. The Party transmitting information developed under this Specific Memorandum shall not be responsible for any property damages or personal injury, whether nuclear or nonnuclear, suffered by the receiving Party, its government, its contractors and subcontractors, their employees and third parties resulting from the application or use of such information developed, exchanged or transferred between DOE and JAERI or DOE contractors and JAERI under the Specific Memorandum. C. Disclosure of information developed and included in reports under the Specific Memorandum may take the form of joint publications or individual publications. Such disclosures of information shall be carried out under and subject to the Nuclear R&D Agreement .
View SourceView Similar (2)
Information Use and Disclosure. EMERALD collects personal information from the Deliverer and Warehouse for the purpose of providing the services set out in these terms and conditions. The Warehouser and Deliverer agree that their delivery details may be provided by EMERALD at its discretion to: (a) marketers /traders for the purpose of promoting their services to the Warehouser and Deliverer; (b) the National Grower Register Pty Ltd (“NGR”) or its agents for the purposes of the NGR or for promoting goods or services of other companies of relevance to the Warehouser; and (c) the relevant regulator of the Heavy Vehicle National Law, (d) any adviser, auditor or member of the EMERALD Group, including companies which may be located in Singapore and Japan and otherwise may only be provided to other parties with the consent of the Warehouser. EMERALD’s privacy policy is set out on the web site. All notices, requests to access or change information or privacy complaints should be made in writing to “The Privacy Officer”, Emerald Grain ▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇.
View SourceView Similar (2)
Information Use and Disclosure. Except to the extent necessary for performance of the work, citizens should not be required to share information with those engaged by the government in order to access services provided by the government and such information should be used by those engaged by the government only to the extent necessary to perform the work acquired; accordingly, this clause addresses basic requirements for the Contractor’s use and disclosure of government information, which expressly includes, but is not limited to, information provided by or obtained from the citizens. Anonymizing information does not resolve the foregoing concern. This clause should be broadly interpreted to effectuate this intent. Every obligation in this clause is material. Absent express reference to this clause, this clause supersedes any other clause to the extent of any inconsistency unless and to the extent the other clause provides greater protection for government information.
View Source
Information Use and Disclosure. EMERALD collects personal information from the Deliverer and Warehouse for the purpose of providing the services set out in these terms and conditions. The Warehouser and Deliverer agree that their delivery details may be provided by EMERALD at its discretion to: (a) marketers /traders for the purpose of promoting their services to the Warehouser and Deliverer; (b) the National Grower Register Pty Ltd (“NGR”) or its agents for the purposes of the NGR or for promoting goods or services of other companies of relevance to the Warehouser; and (c) any organisation to which the Warehouser has donated Commodity for the purpose of allowing the organization to identify the donor, (d) any adviser, auditor or member of the EMERALD Group, including companies which may be located in Singapore and Japan and otherwise may only be provided to other parties with the consent of the Warehouser. EMERALD’s privacy policy is set out on the web site. All notices, requests to access or change information or privacy complaints should be made in writing to “The Privacy Officer”, Emerald Grain ▇▇▇▇▇ ▇, ▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇.
View Source

Related to Information Use and Disclosure

  • Use and Disclosure All Confidential Information of a party will be held in confidence by the other party with at least the same degree of care as such party protects its own confidential or proprietary information of like kind and import, but not less than a reasonable degree of care. Neither party will disclose in any manner Confidential Information of the other party in any form to any person or entity without the other party’s prior consent. However, each party may disclose relevant aspects of the other party’s Confidential Information to its officers, affiliates, agents, subcontractors and employees to the extent reasonably necessary to perform its duties and obligations under this Agreement and such disclosure is not prohibited by applicable law. Without limiting the foregoing, each party will implement physical and other security measures and controls designed to protect (a) the security and confidentiality of Confidential Information; (b) against any threats or hazards to the security and integrity of Confidential Information; and (c) against any unauthorized access to or use of Confidential Information. To the extent that a party delegates any duties and responsibilities under this Agreement to an agent or other subcontractor, the party ensures that such agent and subcontractor are contractually bound to confidentiality terms consistent with the terms of this Section 11.

  • Permitted Use and Disclosures Each Party hereto may use or disclose Confidential Information disclosed to it by the other Party to the extent such information is included in the Pharmacopeia Technology, Schering Technology or Collaboration Technology, as the case may be, and to the extent (i) such use or disclosure is reasonably necessary and permitted in the exercise of the rights granted hereunder in filing or prosecuting patent applications, prosecuting or defending litigation, (ii) such disclosure is reasonably required to be made to any institutional review board of any entity conducting clinical trials with Agreement Compound(s) and/or Agreement Product(s), or to any governmental or other regulatory agency, in order to gain approval to conduct clinical trials or to market Agreement Compound(s) and/or Agreement Products, (iii) such disclosure is required by law, regulation, rule, act or order of any governmental authority, court, or agency, or is made in connection with submitting required information to tax or other governmental authorities, or (iv) such disclosure or use is reasonably required in conducting clinical trials, or making a permitted sublicense or otherwise exercising license rights expressly granted to it by the other Party pursuant to the terms of this Agreement; in each case, provided that if a Party is required to make any such disclosure of another Party’s Confidential Information, other than pursuant to a confidentiality agreement, it will give reasonable advance notice to the other Party of such disclosure and, save to the extent inappropriate in the case of patent applications, will use its reasonable diligent efforts to secure confidential treatment of such Confidential Information in consultation with the other Party prior to its disclosure (whether through protective orders or otherwise) and disclose only the minimum necessary to comply with such requirements.

  • General Use and Disclosure Provisions Except as otherwise limited in this Section of the Contract, Business Associate may use or disclose PHI to perform functions, activities, or services for, or on behalf of, Covered Entity as specified in this Contract, provided that such use or disclosure would not violate the HIPAA Standards if done by Covered Entity or the minimum necessary policies and procedures of the Covered Entity.

  • Publicity and Disclosures No press releases or public disclosure, either written or oral, of the transactions contemplated by this Agreement, shall be made by a party to this Agreement without the prior knowledge and written consent of Buyer and the Company.

  • Use and Disclosure of PHI Business Associate is limited to the following permitted and required uses or disclosures of PHI: a. Duty to Protect PHI. Business Associate shall protect PHI from, and shall use appropriate safeguards, and comply with Subpart C of 45 CFR Part 164 (Security Standards for the Protection of Electronic Protected Health Information) with respect to EPHI, to prevent the unauthorized Use or disclosure of PHI other than as provided for in this Contract or as required by law, for as long as the PHI is within its possession and control, even after the termination or expiration of this Contract.